RT Journal Article
SR Electronic
T1 Utilizing a wearable smartphone-based EEG for pediatric epilepsy patients in the resource poor environment of Guinea: A prospective study. (N5.001)
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP N5.001
VO 92
IS 15 Supplement
A1 Williams, Jennifer
A1 Cisse, Fodé Abass
A1 Schaekermann, Mike
A1 Sakadi, Foksuna
A1 Tassiou, Nana Rahamatou
A1 BAH, Aissatou Kenda
A1 Hamani, Abdoul Bachir Djibo
A1 Lim, Andrew
A1 Leung, Edward C. W.
A1 Fantaneau, Tadeu A.
A1 Milligan, Tracey
A1 Khatri, Vidita
A1 Hoch, Daniel
A1 Vyas, Manav
A1 Lam, Alice
A1 Hotan, Gladia
A1 Cohen, Joseph
A1 Law, Edith
A1 Mateen, Farrah
YR 2019
UL http://n.neurology.org/content/92/15_Supplement/N5.001.abstract
AB Objective: To compare the ability of a smartphone-based app, the Smartphone Brain Scanner-2(SBS2), and pre-placed EEG cap (Easycap), costing ~300USD, to detect abnormalities with that of standard EEG.Background: There is a need for reliable, accessible and cost efficient EEG technologies in resource-limited settings. The SBS-2 is a portable, wearable device utilizing a 14 channel EasyCap administered by personnel easily after a few hours training. Data are transmitted via a wireless android tablet and read remotely by specialist neurophysiologists.Design/Methods: Children were enrolled at Ignace Deen Hospital, Conakry, in November 2017. Participants met the ILAE definition of epilepsy and sequentially had a standard 21 lead Xltek EEG and a 14 lead EasyCap EEG utilizing SBS-2 technology. EEGs were read remotely by specialist clinical neurophysiologists in the USA and Canada. Quality scores (0–10, 0 being totally uninterpretable, 10 perfect ) were also provided.Results: 97 patients (49 male, mean age 10 years) were enrolled. One standard (1.0%) and 11(11.3%) of SBS-2 EEGs were uninterpretable due to artefact. Mean quality scores were 7.37 and 6.76 for standard and SBS-2 EEG. Two patients had a standard EEG but not an SBS-2 EEG, yielding 83 pairs of studies for analysis. Mean recording time for standard and SBS-2 EEGs was 22.9 and 27.9 minutes respectively. Fifty-six(67.4%) standard EEGs and 31(37.3%) SBS-2 EEGs were abnormal. The sensitivity and specificity for any abnormality was 0.52 (CI 0.378,0.658) and 0.93 (CI 0.801,1.00). Epileptiform discharges were detected on 21 (25.3%) SBS-2 and 30 (36.1%) of standard EEGs. The SBS-2 had a sensitivity of 0.52 (CI 95% 0.324,0.708) and a specificity of 0.90(CI 95% 0.814,.944) for epileptiform discharges with positive and negative predictive values of 0.762 and 0.758.Conclusions: The SBS-2 application and EasyCap wearable device is easy to administer, moderately sensitive but highly specific for detection of EEG and epileptiform abnormalities in pediatric epilepsies.Disclosure: Dr. Williams has nothing to disclose. Dr. Cisse has nothing to disclose. Dr. Schaekermann has nothing to disclose. Dr. Sakadi has nothing to disclose. Dr. Tassiou has nothing to disclose. Dr. Bah has nothing to disclose. Dr. Djibo Hamani has nothing to disclose. Dr. Lim has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Phillips-Respironics. Dr. Leung has nothing to disclose. Dr. Fantaneau has nothing to disclose. Dr. Milligan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen. Dr. Khatri has nothing to disclose. Dr. Hoch has nothing to disclose. Dr. Vyas has nothing to disclose. Dr. Lam has nothing to disclose. Dr. Hotan has nothing to disclose. Dr. Cohen has nothing to disclose. Dr. Law has nothing to disclose. Dr. Mateen has nothing to disclose.